MindWalk Holdings Corp. emphasizes the importance of a connected, trustworthy biological data layer over AI model size in drug discovery. The company launched ReefIQ™, a biological context layer, and LensAI™, a reasoning platform, aiming to reduce costly AI errors caused by fragmented biological data. This approach contrasts with peers focusing on AI model development or data generation. MindWalk's strategy reflects a maturing AI drug discovery field shifting from model obsession to data integrity, with early revenue growth and a key client contract signaling potential. Risks remain due to its small size, competition, and market adoption uncertainties.
Ether has surged about 11% over the past week, outperforming other major cryptocurrencies like Bitcoin, which rose 4%. This rise is driven by $96 million inflows into U.S. spot ether ETFs, mainly BlackRock’s low-fee funds, while Grayscale’s higher-fe...
Veea Inc. has announced the commercial release of VeeaONE, a full-stack AI infrastructure platform that integrates edge-to-cloud hardware and software. The platform supports VeeaWare middleware on NVIDIA Jetson and x86/Arm servers, enabling secure, l...
Virtuals Protocol has introduced customizable tokenized indexes on the Robinhood Chain, allowing users to combine multiple assets into a single token. This innovation enables users to create and manage their own asset baskets and earn fees when other...
US spot Bitcoin ETFs saw net inflows of $107.8 million on Wednesday, while Ethereum ETFs attracted $53.8 million, signaling renewed institutional interest in crypto funds. Since their launch in January 2024, Bitcoin ETFs have accumulated over $51 bil...
Kaia has signed a strategic partnership with Xilo Labs to integrate Mochi, an onchain asset management platform, into Kaia's ecosystem. This collaboration allows users to invest stablecoins into diversified portfolios backed by tokenized real-world a...
